Cipla's Stock Sees Temporary Dip, But Still Performing Well with 'Buy' Call from MarketsMOJO
Despite underperforming the Sensex in the short term, Cipla's stock remains above its moving averages and has shown a possible trend reversal after three days of gains.
Cipla, a leading pharmaceutical company, experienced a -3.2% drop in its stock price on October 10th, 2024, closing at Rs 1630.75. However, this should not worry investors as the stock still has a 4.44% difference from its 52-week high and has outperformed the sector by -1.81%. The stock's moving averages are positive and it has a 'Buy' call from MarketsMojo. Despite underperforming the Sensex in the short term, Cipla's stock remains above its moving averages and has shown a possible trend reversal after three days of gains.
Cipla ., a leading pharmaceutical company in the largecap industry, has recently seen a dip in its stock price. On October 10th, 2024, the company's stock fell by -3.2%, closing at Rs 1630.75. However, this dip should not be a cause for concern for investors, as MarketsMOJO has given a 'Buy' call for the stock.
Despite the recent drop, Cipla's stock is still performing well, with a 4.44% difference from its 52-week high of Rs 1702. The stock has also outperformed the sector by -1.81% today. It is worth noting that this drop comes after three consecutive days of gains for the stock, indicating a possible trend reversal.
On the intraday front, Cipla's stock touched a low of Rs 1623.4, a decrease of -3.43%. However, the stock's moving averages are still positive, with it being higher than the 50-day, 100-day, and 200-day moving averages. It is only lower than the 5-day and 20-day moving averages.
In comparison to the Sensex, Cipla's stock has underperformed in the past day and month, with a -3.26% and -0.57% difference, respectively. However, the Sensex has also seen a slight decrease in performance during the same time periods.
Overall, Cipla's stock may have seen a dip, but it is still performing well and has a 'Buy' call from MarketsMOJO. Investors should not be discouraged by this temporary drop and can continue to have confidence in the company's growth in the pharmaceutical industry.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
